newsfilter
← Latest News
GlobeNewswire·

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company